Trial Profile
A Phase II Randomized, Double-Blind, Placebo-Controlled Multi-Center Study to Assess the Safety, Tolerability, and Efficacy of Riociguat in Patients With Sickle Cell Diseases
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Jul 2023
Price :
$35
*
At a glance
- Drugs Riociguat (Primary)
- Indications Sickle cell anaemia
- Focus Adverse reactions
- 11 Jul 2022 Status changed from recruiting to completed.
- 05 Jan 2022 Planned primary completion date changed from 1 Dec 2021 to 1 Jun 2022.
- 06 Jan 2021 Planned End Date changed from 1 Jun 2021 to 1 Jun 2022.